Evidence map›Paper›PMID 39867897›Full record

ArticleFrontiers in immunology2024

Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study).

Kuniaki Sato, Satoshi Toh, Taku Murakami, Takafumi Nakano, Takahiro Hongo, Mioko Matsuo, Kazuki Hashimoto, Masashi Sugasawa, Keisuke Yamazaki, Yushi Ueki and 19 more

Abstract readClinical StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Kuniaki SatoDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Satoshi TohDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Taku MurakamiShowa Denko Materials America, R&D Center, Irvine, CA, United States.
Takafumi NakanoDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Takahiro HongoDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Mioko MatsuoDepartment of Otolaryngology, Head and Neck Surgery, Graduate School of Medical Science, Kyushu University, Fukuoka, Fukuoka, Japan.
Kazuki HashimotoDepartment of Otolaryngology, Head and Neck Surgery, Graduate School of Medical Science, Kyushu University, Fukuoka, Fukuoka, Japan.
Masashi SugasawaDepartment of Head & Neck Surgery, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Keisuke YamazakiDepartment of Otolaryngology, Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan.
Yushi UekiDepartment of Otolaryngology, Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan.
Torahiko NakashimaDepartment of Otorhinolaryngology, National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan.
Hideoki UryuDepartment of Otorhinolaryngology, National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan.
Takeharu OnoDepartment of Otolaryngology, Head and Neck Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Hirohito UmenoDepartment of Otolaryngology, Head and Neck Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Tsutomu UedaDepartment of Otorhinolaryngology, Head and Neck Surgery Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Hiroshima, Japan.
Satoshi KanoDepartment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Akihito WatanabeDepartment of Otolaryngology, Head and Neck Surgery, Keiyukai Sapporo Hospital, Sapporo, Hokkaido, Japan.
Ichiro OtaDepartment of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashiwara, Nara, Japan.
Nobuya MondenDepartment of Head and Neck Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Shigemichi IwaeDepartment of Head and Neck Surgery, Hyogo Cancer Center, Akashi, Hyogo, Japan.
Takashi MaruoDepartment of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yukinori AsadaDepartment of Head and Neck Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Daisuke SanoDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Hiroyuki OzawaKeio University School of Medicine, Otolaryngology, Head and Neck Surgery, Tokyo, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Takahito FukusumiDepartment of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Muneyuki MasudaDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors (< 20%) demand a robust prognostic biomarker. This nationwide multi-centric prospective study aimed to identify a plasma exosome (PEX) mRNA signature, which serves as a companion diagnostic of nivolumab and provides a biological clue to develop effective therapies for a majority of non-survivors. Methods: Pre-treatment plasmas ( Results: Assays for pre-treatment blood samples ( Conclusion: The PEX mRNA signature could be useful as a companion diagnostic of nivolumab. The combination of an anti-NKG2A antibody (i.e., monalizumab) and nivolumab may serve as a treatment option for non-survivors predicted by a RT-qPCR-based pre-treatment measurement of PEX mRNAs.

Indexed as

Antineoplastic Agents, ImmunologicalBiomarkers, TumorExosomesHead and Neck NeoplasmsNivolumabRNA, MessengerSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedPrognosisProspective StudiesAntineoplastic Agents, ImmunologicalBiomarkers, TumorImmune Checkpoint InhibitorsNivolumabRNA, Messengerbiomarkerexosomehead and neck cancerHLA-Enivolumab

Identifiers

PMID39867897
PMCPMC11758179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.